ESR1 and breast cancer: Since the company has already concluded a clinical trial on the safety and diagnostic value of [64Cu]Cu-SAR-BBN PET/CT for ER/PR-positive metastatic BC, it is likely that the evaluation of the GRPR-targeting theranostic couple using copper radioisotopes will soon be extended also to BC patients (97).